PROX1 是 WHO 分级为 II 级的脑胶质瘤患者生存的预测因子。
PROX1 is a predictor of survival for gliomas WHO grade II.
机构信息
Department of Oncology-Pathology, Karolinska Institutet, CCK R8:05, Karolinska University Hospital, S-17176 Stockholm, Sweden.
出版信息
Br J Cancer. 2011 May 24;104(11):1747-54. doi: 10.1038/bjc.2011.162. Epub 2011 May 10.
BACKGROUND
The clinical course of World Health Organisation grade II gliomas remains variable and their time point of transformation into a more malignant phenotype is unpredictable. Identification of biological markers that can predict prognosis in individual patients is of great clinical value. PROX1 is a transcription factor that has a critical role in the development of various organs. PROX1 has been ascribed both oncogenic and tumour suppressive functions in human cancers. We have recently shown that PROX1 may act as a diagnostic marker for high-grade gliomas. The aim of this study was to address the prognostic value of PROX1 in grade II gliomas.
METHODS
A total of 116 samples were evaluated for the presence of PROX1 protein. The number of immunopositive cells was used as a variable in survival analysis, together with established prognostic factors for this patient group.
RESULTS
Higher PROX1 protein was associated with poor outcome. In the multivariate analysis, PROX1 was identified as an independent factor for survival (P=0.024), together with the presence of mutated isocitrate dehydrogenase 1 R132H protein, and with combined losses of chromosomal arms 1p/19q in oligodendrocytic tumours.
CONCLUSION
PROX1 is a novel predictor of survival for grade II gliomas.
背景
世界卫生组织（WHO）二级胶质瘤的临床病程仍存在差异，其向更恶性表型转化的时间点难以预测。识别能够预测个体患者预后的生物学标志物具有重要的临床价值。PROX1 是一种转录因子，在多种器官的发育中具有关键作用。PROX1 在人类癌症中具有致癌和抑癌功能。我们最近表明，PROX1 可能是高级别胶质瘤的诊断标志物。本研究旨在探讨 PROX1 在二级胶质瘤中的预后价值。
方法
共评估了 116 例样本中 PROX1 蛋白的存在情况。将免疫阳性细胞的数量作为生存分析的变量，与该患者组的既定预后因素一起使用。
结果
较高的 PROX1 蛋白与不良预后相关。在多变量分析中，PROX1 与 IDH1 R132H 蛋白突变的存在以及少突胶质细胞瘤中 1p/19q 染色体臂的联合缺失一起，被确定为生存的独立因素（P=0.024）。
结论
PROX1 是二级胶质瘤患者生存的新预测因子。
Zotero 插件